Reports
Global Idiopathic Intracranial Hypertension Treatment Market Share, Size, Insights, Report, Growth, Analysis, Forecast: By Diagnosis Method: Carbonic Anhydrase Inhibitors, Loop Diuretics, Corticosteroids, Anticonvulsant, Others; By Treatment Channel: Public, Private; Regional Analysis; Market Dynamics; Supplier Landscape; 2023-2031
Global Idiopathic Intracranial Hypertension Treatment Market Outlook
The global idiopathic intracranial hypertension treatment market size is estimated to grow with a CAGR of 4.27% during the forecast period of 2023-2031. The market growth can be attributed to the increase in the number of obese people and rising ageing population, who are more prone to the condition.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Idiopathic Intracranial Hypertension Insights
Increased pressure inside the skull characterizes Intracranial Hypertension (IH). Intracranial refers to inside the skull, and hypertension refers to high blood pressure. Intracranial hypertension is indicated by an abnormally high pressure in the fluid that surrounds the brain (cerebrospinal fluid or CSF). Elevated CSF pressure can result in two complications: severe headache and visual loss.
If the elevated CSF pressure is not treated, it can lead to permanent vision loss or blindness. Former names for IH include pseudotumour cerebri and benign intracranial hypertension, both of which are now considered incorrect. These names do not adequately describe the disorder and minimise its severity.
Women are more likely than men to develop IIH. Women account for approximately 19% of people with idiopathic intracranial hypertension. The majority are between the age group of 20 and 50.
A sudden, severe headache is the most common symptom of intracranial hypertension. Sometimes the headache is so severe that it wakes the patient up. People suffering from IIH may experience changes in their vision. One may experience double vision or unexpected blind spots. Symptoms of intracranial hypertension may also include:
- Fatigue
- Headaches
- Peripheral (side) vision loss
- Vomiting and nausea
- Shoulder and neck discomfort
- Blindness is only temporary
- Tinnitus (ringing ears)
IIH has an unknown cause. If a cause is found, the condition is referred to as secondary intracranial hypertension rather than idiopathic intracranial hypertension. Cerebrospinal fluid surrounds the brain and spinal cord, protecting these vital tissues from injury. This fluid is produced in the brain and is eventually absorbed into the bloodstream at a rate that allows the brain pressure to remain constant. The increased intracranial pressure caused by pseudotumour cerebri could be due to a problem with the absorption process.
According to the idiopathic intracranial hypertension treatment market research report, the market can be categorised into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Diagnostic Method
- Carbonic Anhydrase Inhibitors
- Acetazolamide
- Methazolamide
- Others
- Loop Diuretics
- Furosemide
- Others
- Corticosteroids
- Anticonvulsant
- Topiramate
- Others
Market Breakup by Treatment Channels
- Public
- Private
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Idiopathic Intracranial Hypertension Epidemiology
Idiopathic intracranial hypertension affects about one in every 100,000 people. Obesity affects approximately 20 young females out of every 100,000.
Therapeutic Landscape of Idiopathic Intracranial Hypertension Treatment Market
In patients with idiopathic intracranial hypertension (IIH), the treatment goal is to preserve optic nerve function while managing increased intracranial pressure (ICP). Obese patients are repeatedly advised to lose weight and eat a low-sodium diet. Exogenous agents that may be linked to increased ICP, should be avoided. The administration of acetazolamide in a dose-proportional to the patient's symptoms, tolerance, and visual function is the first-line treatment.
When there is evidence of progressive visual field loss despite maximal medical treatment, urgent surgical intervention should be considered.
One of the commonly held beliefs about this condition is that pregnancy worsens or causes the onset of symptomatic IIH. However, there is currently little statistical evidence of a causal relationship between pregnancy and IIH, aside from the fact that pregnancy is common in the age group and gender most affected by IIH.
Global Idiopathic Intracranial Hypertension Treatment Market Drivers and Restraints
Factors like the rapid increase in the number of obese people and an ageing population who are more prone to the condition, along with the tremendous growth in obesity due to sedentary lifestyles, are driving the market growth. The rising demand for targeted medicines to treat the condition's complications and the high prevalence of idiopathic intracranial hypertension among women worldwide have a significant impact on the market. The demand is likely to grow further across the globe, especially in North America due to the region's advanced healthcare technology.
On the other hand, the high treatment costs and poor reimbursement policies, particularly in the price-sensitive sector, are expected to hinder the market growth.
Idiopathic Intracranial Hypertension Treatment Market Competitive Landscape
The report gives an in-depth analysis of the key players involved in the global idiopathic intracranial hypertension treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- Teva Pharmaceutical Industries Ltd
- Mylan N.V.
- Pfizer, Inc.
- Upsher-Smith Laboratories, LLC
- Merck & Co., Inc.
- Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
- Astellas Pharma Inc.
- AbbVie Inc.
- Cadila Healthcare Ltd.
- Sanofi
- Sun Pharmaceutical Industries Ltd.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Diagnosis Method |
|
| Breakup by Treatment Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Idiopathic Intracranial Hypertension Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials Synopsis
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Idiopathic Intracranial Hypertension Treatment Market
8.1 Global Idiopathic Intracranial Hypertension Treatment Market Overview
8.2 Global Idiopathic Intracranial Hypertension Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Idiopathic Intracranial Hypertension Treatment Market Historical Value (2016-2022)
8.2.1.2 Global Idiopathic Intracranial Hypertension Treatment Market Forecast Value (2023-2031)
8.2.2 Global Idiopathic Intracranial Hypertension Treatment Market by Diagnosis Method
8.2.2.1 Market Overview
8.2.2.1.1 Carbonic Anhydrase Inhibitors
8.2.2.1.1.1 Acetazolamide
8.2.2.1.1.2 Methazolamide
8.2.2.1.1.3 Others
8.2.2.1.2 Loop Diuretics
8.2.2.1.2.1 Furosemide
8.2.2.1.2.2 Others
8.2.2.1.3 Corticosteroids
8.2.2.1.4 Anticonvulsant
8.2.2.1.4.1 Topiramate
8.2.2.1.5 Others
8.2.3 Global Idiopathic Intracranial Hypertension Treatment Market by Treatment Channel
8.2.3.1 Market Overview
8.2.3.1.1 Public
8.2.3.1.2 Private
8.2.4 Global Idiopathic Intracranial Hypertension Treatment Market by Region
8.2.4.1 Market Overview
8.2.4.1.1 North America
8.2.4.1.2 Europe
8.2.4.1.3 Asia Pacific
8.2.4.1.4 Latin America
8.2.4.1.5 Middle East and Africa
9 North America Idiopathic Intracranial Hypertension Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Idiopathic Intracranial Hypertension Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Idiopathic Intracranial Hypertension Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Idiopathic Intracranial Hypertension Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Idiopathic Intracranial Hypertension Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global Idiopathic Intracranial Hypertension Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Teva Pharmaceutical Industries Ltd
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Mylan N.V.
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Pfizer, Inc.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Upsher-Smith Laboratories, LLC
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Merck & Co., Inc.
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Astellas Pharma Inc.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 AbbVie Inc.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Cadila Healthcare Ltd.
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Sanofi
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Sun Pharmaceutical Industries Ltd.
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
16 Global Idiopathic Intracranial Hypertension Treatment Market- Drug Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market is likely to grow at a CAGR of 4.27% during the forecast period of 2023-2031.
Market growth is driven by an increase in the number of obese people and an ageing population that is more prone to the condition, and the tremendous growth in obesity due to sedentary lifestyles.
Teva Pharmaceutical Industries Ltd, Mylan N.V., Pfizer, Inc., Upsher-Smith Laboratories, LLC, Merck & Co., Inc., Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Astellas Pharma Inc., AbbVie Inc., Cadila Healthcare Ltd., Sanofi, and Sun Pharmaceutical Industries Ltd., among others are the leading companies in the market.
Which factor is restraining the growth of the idiopathic intracranial hypertension treatment market?
High treatment costs and poor reimbursement policies, particularly in the price-sensitive sector, are expected to hinder the market growth.
The early signs of IIP includes headache, blurred vision, and lack of attention.
Weight loss of 6%-10% often results in the remission of idiopathic intracranial hypertension.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$3499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER